Oncologists trace RAS from "undruggable" oncogene to daraxonrasib, which doubled survival in pancreatic cancer and earned a standing ovation at ASCO 2026.
Back
Novel Therapeutic Modalities Reshaping Oncology Care
Dr. Shreyas Kalantri of University of Cincinatti moderated a discussion with Dr. Jia Luo of Dana-Farber Cancer Institute and Dr. Matthew Karr of Rutgers Cancer Institute unpack how RAS inhibitors and bispecific antibodies are reshaping subsequent-line treatment, quality of life, and toxicity management across solid tumors and hematologic cancers.
Novel Therapeutic Modalities Reshaping Oncology Care
Episodes
All
All
Oncologists break down how they weigh trial validity, statistical versus clinical significance, and real-world data when choosing among new therapies like the bispecific tarlatamab.
Two oncologists discuss time toxicity, subcutaneous dosing, and the infrastructure and monitoring challenges limiting community access to CAR T and bispecific therapies.
How solid tumor oncologists are borrowing hematology's CRS and ICANS management playbook as bispecific therapies like tarlatamab bring new toxicities into lung cancer care.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5